Brokerages Set Candel Therapeutics, Inc. (NASDAQ:CADL) Target Price at $18.33

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.3333.

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Monday, September 29th. Stephens restated an “overweight” rating and set a $15.00 price target on shares of Candel Therapeutics in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Citigroup cut their target price on Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, November 14th.

Candel Therapeutics Stock Performance

NASDAQ CADL opened at $5.44 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.25 and a current ratio of 8.25. The stock’s fifty day moving average is $5.27 and its two-hundred day moving average is $5.53. The firm has a market capitalization of $298.66 million, a P/E ratio of -9.54 and a beta of -0.93. Candel Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $13.68.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). On average, research analysts anticipate that Candel Therapeutics will post -1.47 earnings per share for the current year.

Institutional Trading of Candel Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC acquired a new position in Candel Therapeutics in the third quarter valued at about $697,000. Lido Advisors LLC acquired a new position in shares of Candel Therapeutics in the 3rd quarter worth approximately $307,000. BNP Paribas Financial Markets lifted its holdings in shares of Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after acquiring an additional 4,439 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock worth $10,236,000 after purchasing an additional 219,563 shares during the period. Finally, Taylor Financial Group Inc. increased its holdings in Candel Therapeutics by 36.0% in the 3rd quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company’s stock valued at $69,000 after purchasing an additional 3,600 shares during the last quarter. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.